The problem of availability of drugs can be solved by implementation of effective social and economic mechanisms. Aim. To substantiate theoretically the effective management model of pricing for drugs. Materials and methods. The analysis of drug availability has been conducted; the model of pharmaceutical pricing has been proposed.
ISSN 2415-8844 (Online) ISSN 1562-7241 (Print)
The main priorities of the European strategy "Health 2020" is the focus on the high quality and availability of medical and pharmaceutical care, universal coverage of the population. According to the National Drug Policy the state must ensure the overall access to essential drugs based on the rational choice, affordable prices and appropriate financing. In this context, there is a formulary system in Ukraine; the elements of Health Technology Assessments (HTA), medical insurance and reimbursement are implemented.
Currently, the national healthcare system can not fully meet the needs of the population in high-quality and effective medical and pharmaceutical care. Unfortunately, effective mechanisms to provide availability of drugs have not been implemented. The Ukrainian patients pay 95 % of the treatment cost from their own pockets.
The issues of the rational use of drugs do not lose their topicality over the years both from the pharmacotherapeutic and economic point of view. The works of such famous domestic and foreign authors as A. S. Nemchenko, A. A. Kotvitskа, K. L. Kosyachenko, L. V. Galiy, I. V. Kubareva, D. Yu. Belousov, T. Bazargani, J. Carone, K. Ruggeri, N. Pinson, J. Vernon, P. A. Danzon deal with improvement of the state regulation of prices, the rational selection and use of essential drugs, efficiency of the formulary system and HTA. The government of Ukraine initiates new healthcare reforms, including the regulation of drug prices. The previous reforms have been unsuccessful since the process is not scientifically based, correctly organized, transparent and controllable. Therefore, creation of the effective pricing model, which would take into account the results of HTA, appears to be important and necessary at present. This was the aim of this article.
Materials and Methods
The analysis of drug availability was conducted; the efficiency of price regulation mechanisms was assessed; the model of pharmaceutical pricing was developed.
Results and Discussion
The results of the WHO studies indicate that the problem of providing the population with qualitative and affordable drugs is topical not only for the countries with low levels of economic development, but globally as well. Limitations of drug availability in Ukraine are caused by a complex of factors, namely the low level of innovation and investment development of domestic production of drugs and dependence on imports; the high cost of original medicines and the problem of generic bioequivalence verification; lobbying the of the applicants' interests and the complicated procedure of drug registration; irrational selection, drug prescribing and use in practice; the low income of the population; the absence of health insurance and reimbursement; inefficient pricing, etc.
As of 20.09.2016 there were 12839 names of drugs in the State Registry of Medicines of Ukraine, among of them drugs of domestic production -30 %, and foreign drugs -70 %. The volume of drug sales in 2015 was 47.1 billion USD (18 % more than in the previous period) per 1.3 billion packs. Retail sales of drugs in monetary terms increased by 18 % (up to 38.6 billion UAH), in natural units they reduced by 18 % (to 818.6 million packs). The weighted average price for pharmaceutical products increased by 43 % in 2015. According to the "Pharmstandard"/"PharmXplorer" market research analytical system of "Proxima Research" company the cost of one pack of a drug in 2015 was 42.5 UAH (domestic drugs -22.7 UАН, imported drugs -107.8 UAH, being almost 5 times more expensive). The share of domestic drugs in the structure of sales increased to 75 % (in packs); however, it was only 37 % in monetary terms. Most drugs at the Ukraine pharmaceutical market are generic -their share is over 94 %, while in the USA it is -12 %, in Japan -30 %, in Germany -35 %, in France -50 % [1] . Needs in original medicines are provided mostly by imports.
In recent years in Ukraine there was an uncontrollable growth of drug prices caused by devaluation of the national currency and introduction of VAT on drugs. Crisis phenomena in economy and social political life greatly affected the solvency of the population and the healthcare system as a whole. Managing the cost of drugs is crucial for the optimal use of the limited resources of the healthcare system. Trade margins restrictions, reference pricing, registration and monitoring of drug prices, mechanisms of partial reimbursement are used in order to stabilize the drug prices and improve their affordability [2] . To standardize the medical and pharmaceutical care and to provide the rational use of drugs the formulary system was created, the standards of Good Pharmacy Practice (GPP), Good Regulatory Practice (GRP) and Good Practice of pharmacovigilance (GPvP) were implemented. Unfortunately, it should be stated that selection and prescription of drugs are often determined by aggressive marketing policies of pharmaceutical companies, but not by the needs of the individual patient or the healthcare system. In view of the abovementioned, the Good Pharmacotherapeutic Practice was approved by the order of MOH of Ukraine No. 651 dated 26.07.2013. This assumes not only the rational use of drugs according to clinical indications by the minimum price, but also the appropriate use of funds and personal responsibility of the authorities of healthcare institutions for compliance with the requirements of medical normative documents.
It should be noted that the system of the state regulation for prices on drugs in Ukraine is very complicated and inefficient ( Fig.) . This is primarily conditioned by the absence of clear methodological approaches to formation and control of prices for essential drugs. Thus, for the purpose of the price control some regulating lists are used in According to the current legislation there is the limitation of wholesale and retail margins on essential drugs, and declaring of wholesale selling prices for drugs purchased by budgetary funds. Thus, the main regulatory impacts are aimed at setting certain limitations in the wholesale and retail sector. Understanding that the manufacturer's price is a key element in the whole process of pricing it is appropriate to introduce effective mechanisms of the state regulation exactly in this sphere [3] . It is important to achieve a balance of interests between the healthcare system (in relation to cost containment and efficiency improvement, guarantees of drug availability), the population (in relation to safety, quality, availability of drugs and effective treatment) and pharmaceutical industry (in relation to profitability of the domestic industry, intellectual property protection, job retention, public support).
It should be noted that currently there is no approved sectorial method of calculating the cost of drugs. Because of the absence of a unified methodological approach to formation of the production cost of drugs purchased by budgetary funds, there is a groundless overpricing at every stage of the price formation and, an inefficient use of the budget.
Analysis of social economic regulatory lists allows identifying the main problems for their effective use. For example, azithromycin -an antimicrobial agent for systemic use -is presented in the National list and the Budget list under 87 trade names, 19 of them are domestic drugs (23%). As of 21/09/2016 only prices for 46 names of azithromycin (trade names) were declared in the register of wholesale drug prices. We analyzed the prices for azithromycin drugs in the form of tablets/ capsules of 250 mg (6 pcs in a pack). Тhe budget list comprises 40 names of these drugs (including 8 -of the Ukrainian production, 18 -manufactured in India, others -produced in Slovenia, Czech Republic, Poland, Canada, Great Britain, Belarus, Croatia, Serbia, Jordan and Egypt). Of these 40 drugs the wholesale prices were declared for 24 medicines (all of them -of foreign production) (Tab.).
It was not our aim in the study to compare the effectiveness of these drugs. However, it is quite clear that the ratio of price and quality for all these drugs will be significantly different.
As seen from Table, there are significant differences in the values of the declared prices (from 35.20 to 101.77 UAH per a pack) and retail prices (from 28.49 to 161.11 UAH), while the wholesale price for domestic drugs ranges from 32.55 to 72.66 UAH. In conditions of instability manufacturers/applicants lay financial risks to the declared price. It is of interest that some declared prices are significantly higher than the weighted average retail prices. Naturally, it is better for consumers if the choice of products is available, but in this case the quality-safety-price relationship is not evident. Moreover, it is impossible to neutralize the impact of asymmetric information.
The inefficiency of approaches to the state price control on drugs to be procured for the budget was demonstrated on the example of the antimicrobial agent for cording to which the preferential supply and reimbursement are carried out [4] [5] [6] [7] . Objectively growing needs of the healthcare system on the background of limited resources cause the necessity of assessment of the existing and innovative technologies in healthcare in regards to clinical efficiency, economic expediency and safety both for an individual patient and the healthcare system as a whole.
Medical and pharmaceutical care in each country has special features due to the political situation, the socioeconomic level, development of technologies. Thus, a key factor for introduction of innovations in healthcare is availability of resources. "To achieve the best possible health services within the existing resources, implementation of the most efficient technologies should be supported taking into account the institutional, social and ethical issues" [8] .
Within the framework of formation and implementation of national healthcare policies the authorized state bodies make decisions on licensing of certain activities related to the application of healthcare technologies, licensing of drugs and medicinal products for placing them at the market, reimbursement, etc. Regulatory authorities base on the information that comes from producers (applicants) within the legal terms during the licensing, decision making concerning drug registration, and tendering. However, the procedure does not provide comparison of the individual healthcare technology with the existing alternatives to determine the additional advantages from the point of view of the results for a particular patient or society in general. Therefore, the essential influence of information asymmetry on the decision to use HTA should be noted. Fair and reasonable scientific HTA enables to neutralize disadvantages caused by information asymmetry and reduce the risks of making responsible decisions concerning the application of a certain technology [9, 10] .
Decision-making on specific aspects of the healthcare public policy (funding, compensation, investing, planning, etc.) are taken at the macro-or mesolevel by relevant competent authorities/persons. Analysis of the international experience shows that decision-making by politicians and scientists is carried on fundamentally different platforms, according to different criteria. For example, researchers rely on specific scientific data characterized by reliability, evidence, consistency. For politicians the main criteria are relevance, consistency, laconicism and timeliness of information with possible approximate estimates and assumptions, the preference is given to generalized data. Consequently, political decisions are often situational, conditioned by political expediency and not scientifically based [8] .
The main values of the healthcare policy in EU are concentrated around evidential medicine, HTA and analysis of the economic effectiveness [11] . Experts estimate that the main objects of HTA should be as follows: the patient's safety, clinical efficiency, assessment of the cost/benefit ratio, economic efficiency, needs and problems of patients, the impact on the quality of life, availability of medical services, as well as ethical issues in healthcare [6] .
One key element of HTA is comparative effectiveness research (CER). There are two types of CER -rapid assessment and full assessment [1] . The rapid assessment is evaluation of one HTA compared with one or more significant alternative types of intervention for a short period of time (e. g., launching a drug into production). The full assessment by pharmacoeconomic parameters taking into account the impact of HTA on the healthcare system is usually done in a few years after implementation of the technology to the market. At the same time as the reference technology different variants can be used, the "existing practice" or other alternatives are the most common, cheapest, most effective technologies meeting the standards and clinical practice guidelines.
CoNCLUSIoNS The analysis of prices on essential drugs has shown their low availability and inefficiency of regulation mechanisms. The effective social model of pharmaceutical pricing has been developed. In conditions of limited resources of the healthcare system it is considered to be appropriate to introduce a consolidated list of drugsthe National list formed according to the WHO concept. This list will serve as a basis for public procurement, reimbursement schemes, preferential provision of drugs, as well as management of local production of drugs in development of import substitution. To identify the optimal drugs for their inclusion in the National list is important to use the results of HTA.
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